Orasure Technologies Inc (OSUR) Q4 2025 Earnings Call

Concluded Feb 25, 2026

Feb 25, 2026 0 turns

Period: FY2025 Q4
Runtime: —
Sources: 3 artifacts

Slides 10 8-K 10-K

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. slides, 8-K earnings release, 10-K stay in one workspace.

Product pipeline and FDA submissions 25 International expansion and nearshoring 15 BiMedomics / Sickle SCAN integration 8 Operational efficiency and manufacturing consolidation 8 Sample Management Solutions growth 6 Funding environment stabilization 5

Management tone

Positive

Net tone +35 · moderate hedging

Grounding quotes

“we are seeing increasing signs of stability in key segments, including improved visibility to funding for important testing and research programs, and we are excited by several near-term catalysts for growth”
“We also anticipate modest contributions to SMS revenue growth from the academic and government segments as NIH funding returns to a more regular cadence”
“We are pleased with this progress. While we appreciate the self-funding space in public health, we are optimistic about the opportunities for market and segment expansion beyond that”
“We see this as an exciting opportunity that adds to our existing sales rather than cannibalizing them”

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Revenue · derived Q4 $26.76M -28.5% YoY

Gross margin · derived Q4 41.0% +4.8 pp YoY

Net income · derived Q4 -$19.29M